← Eichor
Condition: Fgfr2 Gene Rearrangement Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Fgfr2 Gene Rearrangement

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Phase 2 · 44 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT05678270Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Phase 1 · 4 location(s) · Tyra Biosciences, Inc · NCT06160752Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Phase 2 · 65 location(s) · Taiho Oncology, Inc. · NCT05727176A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Phase 2 · 19 location(s) · Elevar Therapeutics · NCT07359820A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients
Phase 2 · 2 location(s) · Mehmet Akce · NCT06728410
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.